Coccidioidomycosis among persons undergoing lung transplantation in the coccidioidal endemic region
Affiliation
Univ Arizona, Coll Med, Div Pulm, Dept MedUniv Arizona, Coll Med, Div Infect Dis, Dept Med
Issue Date
2017-08
Metadata
Show full item recordPublisher
WILEYCitation
Chaudhary, S, Meinke, L, Ateeli, H, Knox, KS, Raz, Y, Ampel, NM. Coccidioidomycosis among persons undergoing lung transplantation in the coccidioidal endemic region. Transpl Infect Dis. 2017; 19:e12713. https://doi.org/10.1111/tid.12713Journal
TRANSPLANT INFECTIOUS DISEASERights
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background Coccidioidomycosis, an endemic fungal infection, is more likely to be symptomatic and severe among those receiving allogeneic transplants. While several case series have been published for various transplanted organs, none has described the incidence and outcomes in those receiving lung transplants within the coccidioidal endemic region. Methods Patients receiving a heart-lung, single-lung, or bilateral-lung transplantation at the University of Arizona between 1985 and 2009 were retrospectively reviewed. Results Coccidioidomycosis occurred post transplantation in 11 (5.8%) of 189 patients. All but one patient was diagnosed with pulmonary coccidioidomycosis and only one had a history of prior coccidioidomycosis. Two patients received transplants from donors found to have coccidioidomycosis at the time of transplantation and one death was directly attributed to coccidioidomycosis. The risk of developing active coccidioidomycosis was significantly higher if the patient did not receive some type of antifungal therapy post transplantation (P<.001). Conclusion Within the coccidioidal endemic region, post-transplantation coccidioidomycosis was a definable risk among lung transplant recipients. Use of antifungals appeared to reduce this incidence of disease. Almost all cases resulted in pulmonary disease, suggesting that the lung is the primary site of infection.Note
12 month embargo; published online: 28 April 2017ISSN
13982273Version
Final accepted manuscriptAdditional Links
http://doi.wiley.com/10.1111/tid.2017.19.issue-4ae974a485f413a2113503eed53cd6c53
10.1111/tid.12713